Brendel Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-7,010
Closed -$512K 97
2023
Q3
$512K Buy
+7,010
New +$560K 0.76% 32
2023
Q2
Sell
-8,333
Closed -$635K 93
2023
Q1
$635K Buy
8,333
+196
+2% +$16.3K 0.47% 53
2022
Q4
$675K Buy
8,137
+822
+11% +$66.5K 1.35% 25
2022
Q3
$580K Buy
+7,315
New +$617K 1.38% 27

Other funds holding XBI

Brendel Financial Advisors's XBI Position: Q4 2023 in Review

Brendel Financial Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 7,010 shares — an estimated $512K sold.

Brendel Financial Advisors first reported a position in XBI in Q3 2022 and held it in 4 quarters. The position peaked at $675K in Q4 2022. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

  • Brendel Financial Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
  • Brendel Financial Advisors sold 7,010 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $512K.
  • Brendel Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and held it in 4 quarters.
  • Brendel Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $675K in Q4 2022.
  • 745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Brendel Financial Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.